Browsing Tag

BTN3A

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC…

Eli Pacheco Nov 11, 2022 0

Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille,…

Health

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical…

Eli Pacheco Jun 13, 2022 0

Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird,…

Health

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa…

Eli Pacheco Nov 13, 2021 0

Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses…